Pfizer Expands its Voluntary Recall of Chantix (varenicline) - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Pfizer Expands its Voluntary Recall of Chantix (varenicline) Pfizer expanded its voluntary recall of varenicline (Chantix) to 12 lots to the consumer level. Pfizer is recalling these lots due to the presence of N-nitroso-varenicline above the company's acceptable limit for this impurity.  FDA reminds patients taking recalled varenicline to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition. The health benefits of stopping smoking outweigh the cancer risk from the nitrosamine impurity in varenicline. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA